Research programme: hepatitis B virus therapeutics - Benitec

Drug Profile

Research programme: hepatitis B virus therapeutics - Benitec

Alternative Names: BB-101; BB-102; BB-103; BB-HB-331; Hepbarna; Hepbarna™ programme

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Benitec Biopharma - Biomics Biotechnologies (JV)
  • Class Small interfering RNA
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 18 Oct 2017 Benitec Biopharma has patent protection for RNA interference agent in Hepatitis B in USA
  • 19 Apr 2017 Interim pharmacodynamics data from preclinical studies in Hepatitis B presented at The International Liver Congress 2017 (ILS-2017)
  • 07 Mar 2017 Benitec Biopharma announces intention to submit IND for either BB 103 or BB 101 to US FDA by the end of 2017 (Benitec BioPharma 20-F, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top